Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein A TawbiPeter A ForsythAlain AlgaziOmid HamidF Stephen HodiStergios J MoschosNikhil I KhushalaniKarl LewisChristopher D LaoMichael A PostowMichael B AtkinsMarc S ErnstoffDavid A ReardonIgor PuzanovRagini R KudchadkarReena P ThomasAhmad TarhiniAnna C PavlickJoel JiangAlexandre AvilaSheena DemeloKim MargolinPublished in: The New England journal of medicine (2018)
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases. (Funded by Bristol-Myers Squibb and the National Cancer Institute; CheckMate 204 ClinicalTrials.gov number, NCT02320058 .).